Enrique Herrera-Acosta
Research Subjects
Enrique Herrera-Acosta has a total of 181 co-authors. Here are the top co-authors by number of shared publications:
Enrique Herrera-Ceballos
Department of Dermatology, Hospital Universitario Virgen de la Victoria, Málaga, Spain
6 shared publications- Jorge Alonso Suárez-Pérez
Dermatology Department, Hospital Regional Universitario
6 shared publications E. Herrera
5 shared publications- Eduardo Nagore
Department of Dermatology, Instituto Valenciano de Oncología, 46009 Valencia, Spain
5 shared publications - Antonio Tejera Vaquerizo
Servicio de Dermatología, Instituto Dermatológico GlobalDerm, Palma del Río, Córdoba, España; Unidad de Oncología Cutánea, Hospital San Juan de Dios, Córdoba, España
4 shared publications Enrique Herrera
Dermatology Department, Hospital Universitario Virgen de la Victoria, 29071-Málaga, Spain, Dermatology and Medicine Department
4 shared publications
Latest Publications
- Open Access
- 22 June 2026
- Published by Taylor & Francis in Journal of Dermatological Treatment
- Vol. 37 (1) , 2672801
Predictors of optimal disease control in atopic dermatitis with abrocitinib: a real-world study
Abrocitinib is approved for moderate-to-severe atopic dermatitis (AD); however, real-world data evaluating its efficacy in AD control using multidimensional-treatment-targets like optimal-disease-control (ODC) and moderate-disease-control (MDC) remain limited. This study aimed to assess the proportion of patients with moderate-to-severe AD achieving ODC and MDC during abrocitinib-treatment and to explore associated factors. Retrospective multicentric study including patients with moderate-to-severe AD receiving abrocitinib across five hospitals. Disease severity was assessed using clinician-reported-outcomes (EASI, SCORAD, IGA, BSA) and patient-reported-outcomes (peak-pruritus and sleep-disturbance NRS) at baseline and follow-ups. ODC and MDC were defined according to consensus-based criteria, integrating clinician- and patient-reported outcomes. Fifty-four patients were included (35.1 years; 68.5% men; baseline EASI 25.7 and peak-pruritus NRS 7.5). At final visit (variable follow-up across patients; mean 20.9 weeks), EASI and peak-pruritus NRS decreased to 8.7 and 3.3, respectively. ODC was achieved by 43.8% of patients and MDC by 59.4%. ODC was associated with lower baseline BSA and SCORAD, lower prevalence of allergic conjunctivitis, fewer prior systemic treatments, and less frequent facial involvement. In real-world practice, a substantial proportion of patients treated with abrocitinib achieved ODC and MDC. Lower baseline severity and fewer prior systemic therapies were associated with ODC.
- 22 June 2026
- Published by Taylor & Francis in Journal of Dermatological Treatment
- Vol. 37 (1) , 2672801
Open AccessPredictors of optimal disease control in atopic dermatitis with abrocitinib: a real-world study
Abrocitinib is approved for moderate-to-severe atopic dermatitis (AD); however, real-world data evaluating its efficacy in AD control using multidimensional-treatment-targets like optimal-disease-control (ODC) and moderate-disease-control (MDC) remain limited. This study aimed to assess the proportion of patients with moderate-to-severe AD achieving ODC and MDC during abrocitinib-treatment and to explore associated factors. Retrospective multicentric study including patients with moderate-to-severe AD receiving abrocitinib across five hospitals. Disease severity was assessed using clinician-reported-outcomes (EASI, SCORAD, IGA, BSA) and patient-reported-outcomes (peak-pruritus and sleep-disturbance NRS) at baseline and follow-ups. ODC and MDC were defined according to consensus-based criteria, integrating clinician- and patient-reported outcomes. Fifty-four patients were included (35.1 years; 68.5% men; baseline EASI 25.7 and peak-pruritus NRS 7.5). At final visit (variable follow-up across patients; mean 20.9 weeks), EASI and peak-pruritus NRS decreased to 8.7 and 3.3, respectively. ODC was achieved by 43.8% of patients and MDC by 59.4%. ODC was associated with lower baseline BSA and SCORAD, lower prevalence of allergic conjunctivitis, fewer prior systemic treatments, and less frequent facial involvement. In real-world practice, a substantial proportion of patients treated with abrocitinib achieved ODC and MDC. Lower baseline severity and fewer prior systemic therapies were associated with ODC.
- Open Access
- 1 January 2026
- Published by Wiley in Dermatologic Therapy
- Vol. 2026 (1) , 8672172
Efficacy and Safety of Bimekizumab Without an Induction Regimen in Patients With Moderate‐to‐Severe Plaque Psoriasis: A Real‐World Clinical Practice Study
Background: In clinical practice, some patients present with moderate baseline inflammatory burden (Psoriasis Area and Severity Index [PASI] 5–10), in whom the need for an induction phase with bimekizumab remains uncertain. The aim was to evaluate, under real‐world conditions, whether initiating treatment without an induction regimen allows comparable clinical responses in patients with lower baseline inflammatory burden. Methods: A prospective observational study was conducted including 65 adult patients with moderate‐to‐severe plaque psoriasis treated with bimekizumab with an induction regimen ( n = 39) or without induction ( n = 26) and followed for 24 weeks. The noninduction strategy was preferentially used in patients with lower baseline inflammatory activity according to clinical judgment. Clinical efficacy outcomes were analysed at baseline and Week 24, with PASI90 as the primary endpoint, and adverse events and treatment discontinuations were also recorded. Results: Baseline PASI was higher in the induction group (12.3 ± 4.2) than in the noninduction group (6.9 ± 2.5; p < 0.001). At Week 24, mean PASI was 0.70 ± 1.05 in the induction group and 0.40 ± 0.49 in the noninduction group. PASI90 response rates were 69% and 73%, respectively ( p = 0.79). The overall incidence of mucocutaneous candidiasis was 9.2% (6/65), occurring exclusively in the induction group (15.4% vs 0%; p = 0.03). Two patients required discontinuation. Conclusions: In patients with lower baseline inflammatory burden, a noninduction strategy achieved high clinical responses comparable to the standard induction regimen at 24 weeks. Lower drug exposure may be associated with a favourable safety profile in selected patients.
- 1 January 2026
- Published by Wiley in Dermatologic Therapy
- Vol. 2026 (1) , 8672172
Open AccessEfficacy and Safety of Bimekizumab Without an Induction Regimen in Patients With Moderate‐to‐Severe Plaque Psoriasis: A Real‐World Clinical Practice Study
Background: In clinical practice, some patients present with moderate baseline inflammatory burden (Psoriasis Area and Severity Index [PASI] 5–10), in whom the need for an induction phase with bimekizumab remains uncertain. The aim was to evaluate, under real‐world conditions, whether initiating treatment without an induction regimen allows comparable clinical responses in patients with lower baseline inflammatory burden. Methods: A prospective observational study was conducted including 65 adult patients with moderate‐to‐severe plaque psoriasis treated with bimekizumab with an induction regimen ( n = 39) or without induction ( n = 26) and followed for 24 weeks. The noninduction strategy was preferentially used in patients with lower baseline inflammatory activity according to clinical judgment. Clinical efficacy outcomes were analysed at baseline and Week 24, with PASI90 as the primary endpoint, and adverse events and treatment discontinuations were also recorded. Results: Baseline PASI was higher in the induction group (12.3 ± 4.2) than in the noninduction group (6.9 ± 2.5; p < 0.001). At Week 24, mean PASI was 0.70 ± 1.05 in the induction group and 0.40 ± 0.49 in the noninduction group. PASI90 response rates were 69% and 73%, respectively ( p = 0.79). The overall incidence of mucocutaneous candidiasis was 9.2% (6/65), occurring exclusively in the induction group (15.4% vs 0%; p = 0.03). Two patients required discontinuation. Conclusions: In patients with lower baseline inflammatory burden, a noninduction strategy achieved high clinical responses comparable to the standard induction regimen at 24 weeks. Lower drug exposure may be associated with a favourable safety profile in selected patients.
- 1 November 2015
- Published by JLE in European Journal Of Dermatology
- Vol. 25 (6) , 623-624
Treatment of actinic cheilitis with methyl aminolevulinate photodynamic therapy and light fractionation: a prospective study of 10 patients
- 1 November 2015
- Published by JLE in European Journal Of Dermatology
- Vol. 25 (6) , 623-624
Treatment of actinic cheilitis with methyl aminolevulinate photodynamic therapy and light fractionation: a prospective study of 10 patients
- Open Access
- 1 September 2015
- Published by Elsevier in European Journal of Cancer
- Vol. 51 (13) , 1780-1793
Effect of time to sentinel-node biopsy on the prognosis of cutaneous melanoma
- 1 September 2015
- Published by Elsevier in European Journal of Cancer
- Vol. 51 (13) , 1780-1793
Open AccessEffect of time to sentinel-node biopsy on the prognosis of cutaneous melanoma
- 1 June 2015
- Published by Wolters Kluwer Health in Melanoma Research
- Vol. 25 (3) , 269-272
Defining the dermoscopic characteristics of fast-growing cutaneous melanomas
A high growth rate in melanomas has been associated with a more aggressive phenotype and worse survival. The aim of this study was to define the dermoscopic characteristics associated with this type of cutaneous melanoma. We carried out a retrospective study of 132 cutaneous melanomas, analyzing certain clinical characteristics and the most important dermoscopic variables related to the melanomas. Fast-growing melanomas were considered to be those with a growth rate of more than 0.5 mm per month. Fast-growing melanomas more often lacked an atypical network, were symmetrical, presented ulceration, and were hypopigmented. The dermoscopic vascular pattern often showed atypical irregular vessels and milky-red areas. The association of these two is a specific characteristic. Fast-growing melanomas have a characteristic phenotype and dermoscopy can be useful for their identification.
- 1 June 2015
- Published by Wolters Kluwer Health in Melanoma Research
- Vol. 25 (3) , 269-272
Defining the dermoscopic characteristics of fast-growing cutaneous melanomas
A high growth rate in melanomas has been associated with a more aggressive phenotype and worse survival. The aim of this study was to define the dermoscopic characteristics associated with this type of cutaneous melanoma. We carried out a retrospective study of 132 cutaneous melanomas, analyzing certain clinical characteristics and the most important dermoscopic variables related to the melanomas. Fast-growing melanomas were considered to be those with a growth rate of more than 0.5 mm per month. Fast-growing melanomas more often lacked an atypical network, were symmetrical, presented ulceration, and were hypopigmented. The dermoscopic vascular pattern often showed atypical irregular vessels and milky-red areas. The association of these two is a specific characteristic. Fast-growing melanomas have a characteristic phenotype and dermoscopy can be useful for their identification.
- Open Access
- 1 April 2015
- Published by Elsevier in Actas Dermo-Sifiliograficas
- Vol. 106 (3) , 208-218
Predictors of Sentinel Lymph Node Status in Cutaneous Melanoma: A Classification and Regression Tree Analysis
- 1 April 2015
- Published by Elsevier in Actas Dermo-Sifiliograficas
- Vol. 106 (3) , 208-218
Open AccessPredictors of Sentinel Lymph Node Status in Cutaneous Melanoma: A Classification and Regression Tree Analysis
- 1 September 2014
- Published by JLE in European Journal Of Dermatology
- Vol. 24 (5) , 619-620
Survival rate of etanercept for psoriasis in real life: a multicentre observational study
- 1 September 2014
- Published by JLE in European Journal Of Dermatology
- Vol. 24 (5) , 619-620
Survival rate of etanercept for psoriasis in real life: a multicentre observational study
- 1 September 2014
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 71 (3) , 507-515
The role of accessibility policies and other determinants of health care provision in the initial prognosis of malignant melanoma: A cross-sectional study
- 1 September 2014
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 71 (3) , 507-515
The role of accessibility policies and other determinants of health care provision in the initial prognosis of malignant melanoma: A cross-sectional study
- 17 February 2013
- Published by Wiley in International Journal of Dermatology
- Vol. 52 (3) , 323-326
Birt–Hogg–Dubé syndrome in a patient with melanoma and a novel mutation in the FCLN gene
Birt–Hogg–Dubé syndrome (BHDS) is an autosomal dominant genodermatosis characterized by the presence of three skin tumors (fibrofolliculomas, trichodiscomas, and acrochordons), together with an increased risk for other tumors, especially renal tumors, caused by a mutation in folliculin, an oncogene suppressor protein. The association of this syndrome with melanoma is very unusual. We report the case of a 54‐year‐old man with a history of melanoma who had multiple white facial papules. His son also presented similar facial lesions. Histopathologic study showed fibrofolliculomas. These clinical and histopathologic features suggested the diagnosis of BHDS. Genetic study revealed a novel heterozygous mutation p.S185P in exon 6 of the FLCN gene. To date, the association between melanoma and BHDS has rarely been described. As the pathogenic mechanism responsible for melanoma seems to be the same as that responsible for neoplasms in BHDS, the authors consider the melanoma a manifestation of BHDS. Thus, during the periodic follow‐up of patients with BHDS, we recommend periodic exhaustive skin examination and excisional biopsy of any suspicious pigmented lesion.
- 17 February 2013
- Published by Wiley in International Journal of Dermatology
- Vol. 52 (3) , 323-326
Birt–Hogg–Dubé syndrome in a patient with melanoma and a novel mutation in the FCLN gene
Birt–Hogg–Dubé syndrome (BHDS) is an autosomal dominant genodermatosis characterized by the presence of three skin tumors (fibrofolliculomas, trichodiscomas, and acrochordons), together with an increased risk for other tumors, especially renal tumors, caused by a mutation in folliculin, an oncogene suppressor protein. The association of this syndrome with melanoma is very unusual. We report the case of a 54‐year‐old man with a history of melanoma who had multiple white facial papules. His son also presented similar facial lesions. Histopathologic study showed fibrofolliculomas. These clinical and histopathologic features suggested the diagnosis of BHDS. Genetic study revealed a novel heterozygous mutation p.S185P in exon 6 of the FLCN gene. To date, the association between melanoma and BHDS has rarely been described. As the pathogenic mechanism responsible for melanoma seems to be the same as that responsible for neoplasms in BHDS, the authors consider the melanoma a manifestation of BHDS. Thus, during the periodic follow‐up of patients with BHDS, we recommend periodic exhaustive skin examination and excisional biopsy of any suspicious pigmented lesion.